NASDAQ · Medical - Healthcare Information Services
SCNX (SCNX) Stock
$0.37
-0.60%
NASDAQ: SCNX
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
GlobeNewswire · Jul 9, 2026
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
GlobeNewswire · Jun 18, 2026
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
GlobeNewswire · Jun 9, 2026
EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch
Benzinga · Jun 9, 2026
SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC
ACCESS Newswire · Jun 4, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held13.31%
Institutions Held3.87%
Institutions Float Held4.46%
Peer Comparison
About SCNX
SCNX is led by CEO Shankar Hariharan, employs 14 people, headquartered in US, publicly traded since 2014.
SCNX stock trades at $0.37 with a market capitalization of $5.66M. The stock is valued at a price-to-earnings (P/E) ratio of -0.16, price-to-book of 0.09, price-to-sales of 12.54. Over the past 52 weeks the stock has ranged between $0.24 and $2.60, and currently trades 85.8% below its 52-week high.
On profitability, SCNX generates a return on equity (ROE) of -0.25%, return on capital employed of -0.02%, an operating margin of -27.19%, a net profit margin of -73.75%.